Contact usContact us

The Company

Domain Therapeutics, a French and Canadian privately-held biopharmaceutical company, is using transmembrane and G Protein-Coupled Receptor (GPCR) targeting for the discovery and development of innovative therapeutics for the treatment of Central Nervous System (CNS) diseases and cancer.

Using its commercially proven candidate discovery engine (Takeda, Merck Serono and ONO Pharmaceutical), Domain has created a pipeline of high-value projects and partnerships. Validating this approach, two projects discovered by Domain Therapeutics technologies are planned to enter clinical Phase I in early and late 2016.

Domain Therapeutics applies a multi-string corporate strategy to grow its business through:

  • validation of its technologies through collaborative partnerships with Pharma/Biotechs,
  • generation of an internal pipeline of 1st in class drug candidates for high unmet needs in CNS and oncology,
  • valuation of its preclinical assets through spin-out vehicles, financed by leading investment funds or supported by development-only companies.

Domain Therapeutics
Last News


In order to keep on track with our fast evolution, our Website is getting a makeover.

Stay tuned to Discover MORE Than You Think!


Domain Therapeutics secures €6 million ($6.7M) debt financing 

Download the PDF file to learn more  

"A few words from Pascal Neuville" 


Domain Therapeutics obtient 6 millions d'euros de financement par l’emprunt

Téléchargez le PDF pour en savoir plus 


Pascal Neuville (CEO), Stanislas Malmezat (CFO) and Marjorie Sidhoum (Director of Business Operations) will be attending the JP Morgan Healthcare Conference. Come and meet them 

Domain participating the JP Morgan 2020